INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
npj Vaccines
October 2021
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
Nature Communications
May 2020
The Lancet Infectious Diseases
July 2019
| Title | Disease Target | Product |
|---|---|---|
| Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT Molecular Therapy — November 2017 |
hTERT | INO-5401 |
| Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity Cancer Immunology Research — September 2013 |
hTERT | INO-5401 |
| A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity Molecular Therapy — February 2017 |
WT1 | INO-5401 |
| CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens Molecular Therapy — March 2020 |
PSA | INO-5151 |
| Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses Human Vaccines — January 2011 |
PSA, PSMA | INO-5401 |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2022 INOVIO Pharmaceuticals. All rights reserved.
